Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

• ClinicalTrials.gov Identifier: NCT03951259
• Recruitment Status: Unknown
• First Posted: May 15, 2019
• Last Update Posted: September 4, 2019
• Sponsor: RenJi Hospital
• Collaborator: Jiangsu ZuoYou Medicine Co., Ltd.
• Information provided by (Responsible Party): RenJi Hospital

Study Description

Brief Summary:

This is a single-center, randomized, double-blind, placebo-controlled, phase 2 study. The purpose of the study is to initially evaluate the safety and efficacy of SM934 combined with steroids compared to placebo in adult subjects with active systemic lupus erythematosus (SLE) over a 12-week period.

Condition or disease	Intervention/treatment	Phase
Systemic Lupus Erythematosus	Drug: SM934; Drug: Placebos	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 48 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of SM934 in Adult Subjects With Active Systemic Lupus Erythematosus
• Actual Study Start Date: July 24, 2019
• Estimated Primary Completion Date: December 31, 2020
• Estimated Study Completion Date: December 31, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: SM934 10mg; SM934 10mg（1 tablet）+Placebo（4 tablets）p.o. qd in combination with steroids	Drug: SM934; In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
Experimental: SM934 30mg; SM934 10mg（3 tablet）+ Placebo（2 tablets）p.o. qd in combination with steroids	Drug: SM934; In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
Experimental: SM934 50mg; SM934 10mg（5 tablet）p.o. qd in combination with steroids	Drug: SM934; In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
Placebo Comparator: Placebo; Placebo（5 tablets）p.o. qd in combination with steroids	Drug: Placebos; The placebo pills are made identical to the investigating SM934 in appearance.

Outcome Measures

Primary Outcome Measures :

1. Percentage of Subjects with Lupus Low Disease Activity Score (LLDAS) in each group [ Time Frame: Week 12 ]

   LLDAS is defined as meeting the following criteria:

   1. SLEDAI-2K ≤4, with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis), and no reported fever, hemolytic anemia, or gastrointestinal activity)
   2. No new disease activity compared with the previous assessment (no new British isles lupus assessment group (BILAG) A domain score or no more than 1 new BILAG B domain score)
   3. PGA ≤1 on a 0-3 scale visual visual analogue scale (VAS)
   4. A current prednisone (or equivalent) dose of ≤7.5 mg daily
   5. Well-tolerated standard maintenance doses of permitted immunosuppressive drugs
2. Percentage of Subjects with Systemic Lupus Erythematosus Responder Index - 4 (SRI-4) response in each group [ Time Frame: Week 12 ]

   SRI-4 response is defined as:

   1. ≥ 4-point reduction from baseline in SLEDAI-2K score
   2. No new BILAG A and no more than 1 new BILAG B domain score
   3. No worsening from baseline in the PGA (<10% worsening from baseline).
3. Percentage of Subjects with Treatment-Emergent Adverse Events (TEAEs) in each group [ Time Frame: Baseline through Week 13 ]
   Percentage of Subjects with TEAEs in each group

Secondary Outcome Measures :

1. Percentage change of SLEDAI-2000 and Physician Global Assessment (PGA) from baseline in each group [ Time Frame: Week 12 ]
   Percentage change of SLEDAI-2000 and PGA from baseline in each group
2. Percentage of Subjects with 30% improvement in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score in each group [ Time Frame: Week 12 ]
   Percentage of subjects who have at least 30% improvement in CLASI score compared to baseline.
3. Change of SLICC/ACR from baseline [ Time Frame: Week 12 ]
   Change of SLICC/ACR score from baseline
4. Percentage of subjects and number of days with steroids dose equal or less to prednisone 7.5mg per day [ Time Frame: Week 12 ]
   Percentage of subjects and number of days with steroids dose equal or less to prednisone 7.5mg per day
5. Percentage of subjects with Proteinuria < 0.5g/24h in each group [ Time Frame: Week 12 ]
   Percentage of subjects with 24hour urine protein level less than 0.5g in each group
6. Percentage change of complement 3 (C3) and complement 4 (C4) from baseline in each group [ Time Frame: Week 12 ]
   Percentage change of complement 3 (C3) and complement 4 (C4) from baseline in each group
7. Percentage change of anti-dsDNA level from baseline in each group [ Time Frame: Week 12 ]
   Percentage change of anti-dsDNA level from baseline in each group
8. Time to SLE flare and Percentage of subjects with SLE flare [ Time Frame: Baseline through week 12 ]
   SLE flare is defined as: Compared to baseline, one new BILAG A or more than 1 new BILAG B domain score. Time to SLE flare is defined as the date of SLE flare minus the date of treatment initiation plus one.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age: 18 to 70;
• Have a clinical diagnosis of SLE according to SLICC-2012 classification criteria;
• Have active SLE with SLEDAI-2k ≥ 6;
• Have positive anti-nuclear antibody (ANA) test results;
• Are on a stable steroids treatment (equals to prednison more than 7.5mg daily but no more than 0.5mg/kg/d) for SLE for at least 30 days prior to first dose of study agent;
• Females of childbearing age are willing to use appropriate contraception;
• Are voluntary to to provide and sign voluntary informed consent is given;

Exclusion Criteria:

• Have any unstable or progressive manifestation of SLE, including but not limited to Central nervous system (CNS) involvement, transverse myelitis, systemic vasculitis, vasculitis with GI involvement, severe or rapidly progressive lupus nephritis, lupus nephritis with proteinuria > 3g/24h, pulmonary hemorrhage, myocarditis;
• Have abnormal liver function test or renal function test: Alanine aminotransferase（ALT）or aspartate aminotransferase (AST) >2 upper limit of normal (ULN); Gamma-glutamyl transferase (GGT) >1.5 ULN; Creatinine or Blood urea nitrogen (BUN) >1.5 ULN;
• Have a history of acute myocardiac infarction, unstable angina, severe arrhythmias within 6 months prior to first dose of study agent;
• Have any major illness/condition or evidence of an unstable clinical condition not due to SLE (eg, cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, psychiatric), which, in the Investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study;
• Have any acute or chronic infectious disease, which requires medical intervention;
• Have a history of cancer within the last 5 years, except for adequately treated skin cancer, or carcinoma in situ of the uterine cervix;
• Have a planned surgical procedure;
• Have received a biologic investigational agent in the past one year;
• Have received the following treatment within 30 days prior to first dose of study agent: live vaccine; change of glucocorticoids dose; IV, intra-muscular (IM), intra-articular (IA) administration of glucocorticoids; other immunosuppressants/immunomodulators; anti-malarial drugs; traditional medicines which has proved to be effective in SLE;
• Have had a major organ transplant;
• Have a history of HIV, or test positive at screening for HIV;
• Test positive for Hepatitis B virus (HBV)-DNA or Hepatitis C virus (HCV)-RNA;
• Have or have had a substance abuse (drug, alcohol) problem in the past one year;
• Are currently using or planned to use estrogen-containing contraceptive methods;
• Have enrolled in an investigational study within 3 months prior to first dose of study agent;
• Investigator considers candidates not appropriating for the study.

Contacts and Locations

Contacts

Contact: Nan Shen, MD & PhD; +86-21-63260477; nanshensibs@gmail.com

Contact: Huihua Ding, MD; +86-21-53882280; dinghuihua@outlook.com

Locations

China, Shanghai

Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University; Recruiting

Shanghai, Shanghai, China, 200001

Contact: Nan Shen, MD & PhD +86-21-63260477 nanshensibs@gmail.com

Contact: Huihua Ding, MD +86-21-53882280 dinghuihua@outlook.com

Principal Investigator: Nan Shen, MD & PhD

Sub-Investigator: Qiang Guo, MD & PhD

Sub-Investigator: Min Dai, MD

Sub-Investigator: Huihua Ding, MD

Sponsors and Collaborators

RenJi Hospital

Jiangsu ZuoYou Medicine Co., Ltd.

More Information

Additional Information:

Related Info 

Publications:

Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, Zhou Y, He PL, Zhang Y, Yang YF, Li Y, Tang W, Zuo JP. SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. Int Immunopharmacol. 2009 Dec;9(13-14):1509-17. doi: 10.1016/j.intimp.2009.09.003. Epub 2009 Sep 19.

• Responsible Party: RenJi Hospital
• ClinicalTrials.gov Identifier: NCT03951259
• Other Study ID Numbers: SM934
• First Posted: May 15, 2019
• Last Update Posted: September 4, 2019
• Last Verified: September 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Lupus Erythematosus, Systemic; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases